These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6468627)

  • 21. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
    Tyndale RF; Kalow W; Inaba T
    Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.
    Hutzler JM; Walker GS; Wienkers LC
    Chem Res Toxicol; 2003 Apr; 16(4):450-9. PubMed ID: 12703961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.
    Mirghani RA; Yasar U; Zheng T; Cook JM; Gustafsson LL; Tybring G; Ericsson O
    Drug Metab Dispos; 2002 Dec; 30(12):1368-71. PubMed ID: 12433805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
    Allqvist A; Miura J; Bertilsson L; Mirghani RA
    Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of fever on quinine and quinidine disposition in the rat.
    Mansor SM; Ward SA; Edwards G
    J Pharm Pharmacol; 1991 Oct; 43(10):705-8. PubMed ID: 1682445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinidine and dihydroquinidine interactions in human plasma.
    Ueda CT; Makoid MC
    J Pharm Sci; 1979 Apr; 68(4):448-50. PubMed ID: 438966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of epitopes on cytochrome P450 3A4/5 recognized by monoclonal antibodies.
    Parimoo B; Mishin VM; Busch CM; Thomas PE
    Arch Biochem Biophys; 2003 Jun; 414(2):244-54. PubMed ID: 12781776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
    Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
    Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes.
    Broly F; Libersa C; Lhermitte M; Dupuis B
    Biochem Pharmacol; 1990 Mar; 39(6):1045-53. PubMed ID: 2322292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of microsomal metabolism of quinidine in rats.
    Rakhit A; Mico B
    Res Commun Chem Pathol Pharmacol; 1985 Jul; 49(1):109-24. PubMed ID: 4035074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.
    Otton SV; Inaba T; Kalow W
    Life Sci; 1984 Jan; 34(1):73-80. PubMed ID: 6141510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-performance liquid chromatographic method for the quantitation of quinidine and selected quinidine metabolites.
    Hoyer GL; Clawson DC; Brookshier LA; Nolan PE; Marcus FI
    J Chromatogr; 1991 Dec; 572(1-2):159-69. PubMed ID: 1818051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes.
    Thompson KA; Murray JJ; Blair IA; Woosley RL; Roden DM
    Clin Pharmacol Ther; 1988 Jun; 43(6):636-42. PubMed ID: 3378385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of sheep liver homogenates on quinine, quinidine, cinchonine and cinchonidine.
    FRASER GP; KERMACK WO
    Biochem J; 1952 Dec; 52(4):xxvi-xxvii. PubMed ID: 13018323
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibitory effects of quinidine and quinine on liver microsome oxidation enzymes in man and rat.
    Tu ZG; Zhao LL
    Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):541-4. PubMed ID: 9863152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.
    Mirghani RA; Ericsson O; Tybring G; Gustafsson LL; Bertilsson L
    Eur J Clin Pharmacol; 2003 May; 59(1):23-8. PubMed ID: 12743670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.